KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Retained Earnings (2018 - 2025)

Vir Biotechnology's Retained Earnings history spans 8 years, with the latest figure at -$1.2 billion for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 69789.34% to -$1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.2 billion, a 69789.34% decrease, with the full-year FY2025 number at -$1.2 billion, down 69789.34% from a year prior.
  • Retained Earnings hit -$1.2 billion in Q4 2025 for Vir Biotechnology, down from -$1.2 billion in the prior quarter.
  • Over the last five years, Retained Earnings for VIR hit a ceiling of $478.8 million in Q3 2022 and a floor of -$1.2 billion in Q4 2025.
  • Historically, Retained Earnings has averaged -$131.0 million across 5 years, with a median of -$2.1 million in 2025.
  • Biggest five-year swings in Retained Earnings: skyrocketed 22851.12% in 2022 and later plummeted 102570.98% in 2025.
  • Tracing VIR's Retained Earnings over 5 years: stood at -$138.6 million in 2021, then surged by 372.18% to $377.2 million in 2022, then plummeted by 100.22% to -$815000.0 in 2023, then plummeted by 110.67% to -$1.7 million in 2024, then tumbled by 69789.34% to -$1.2 billion in 2025.
  • Business Quant data shows Retained Earnings for VIR at -$1.2 billion in Q4 2025, -$1.2 billion in Q3 2025, and -$2.2 million in Q2 2025.